Nel ASA's Financial Results: Impairments Overshadow Record Order Intake

Nel's FY 2025 loss widened on major asset write-downs, overshadowing a 364% Q4 order surge. Analysts turn cautious as the company invests in next-gen tech.

Norwegian hydrogen technology company Nel ASA concluded its 2025 fiscal year with a significantly widened loss, despite a powerful surge in new orders during the final quarter. Substantial asset write-downs weighed heavily on the balance sheet, prompting a cautious response from market analysts.

Analyst Sentiment Cools Following Earnings

The market's reaction to the annual figures has been measured. Within the past 48 hours, Berenberg Bank reiterated a "Hold" rating on the stock, while analysts at Citigroup reduced their price target from 2.70 NOK to 2.40 NOK. These assessments reflect the immediate financial pressures revealed in the report, even as the company points to a robust future pipeline.

Quarterly Performance Hit by Write-Downs

A detailed look at the fourth quarter reveals the core of the challenge. Nel reported a net loss of 870 million NOK, a stark increase from the 64 million NOK loss recorded in the same period last year. This deterioration was primarily driven by a 799 million NOK impairment charge. The write-downs affected alkaline electrolyser production facilities at the Herøya site, as well as certain business and technology values within the Proton Exchange Membrane (PEM) segment. Concurrently, quarterly revenue declined by approximately 21% to 330 million NOK.

A Contradiction in Orders and Backlog

In contrast to the bottom-line result, the company's order intake presented a dramatically different narrative. New orders in Q4 exploded by 364% to reach 686 million NOK. This surge propelled the total order backlog to 1.319 billion NOK, marking a 34% sequential increase from the previous quarter. Nel's liquidity position remained solid, with 1.62 billion NOK in cash and short-term investments.

Strategic Transition Underway

CEO Håkon Volldal characterized 2025 as a year of technological transition for the firm. Nel has made its final investment decision to industrialize its next-generation pressurised alkaline platform. Key strategic initiatives include a planned doubling of annual capacity at the Herøya plant to 1 GW, alongside the automation of core production steps at its facility in Wallingford, Connecticut. Management emphasizes that improving cost control is a central objective, a crucial factor while the market for green hydrogen infrastructure continues to mature.

Nel's shares are currently trading near their 52-week low, having lost roughly 17% of their value over the past twelve months. The critical question for investors is whether the formidable order intake can offset the current operational weakness. The answer largely depends on the company's ability to move beyond the recent impairment charges and successfully convert its new technology platform into profitable, margin-accretive revenue streams.